Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.013 | 0.0335 | 0.5 |
Brugia malayi | Matrixin family protein | 0.0087 | 0.0047 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0609 | 0.3492 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0609 | 0.3492 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0609 | 0.3492 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0609 | 0.3492 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.1596 | 1 | 0.5 |
Schistosoma mansoni | matrix metallopeptidase-9 (M10 family) | 0.0085 | 0.0037 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.1596 | 1 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.1596 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.1596 | 1 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.1596 | 1 | 0.5 |
Onchocerca volvulus | Matrilysin homolog | 0.008 | 0 | 0.5 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.008 | 0 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0609 | 0.3492 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.1596 | 1 | 0.5 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0609 | 0.3492 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0609 | 0.3492 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0087 | 0.0047 | 1 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.013 | 0.0335 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.1596 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.1596 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
% (functional) | = 17.8 | Percent packed cell volume at 10 mg/kg per day | ChEMBL. | 7277393 |
Days (functional) | = 9.6 | Effect of compound on P-388 lymphocytic leukemia growth at a given dose 15 mg/kg per day ip expressed as average survival days of treated mice | ChEMBL. | 7277393 |
Days (functional) | = 10.4 | Effect of compound on P-388 lymphocytic leukemia growth at a given dose 5 mg/kg per day ip expressed as average survival days of treated mice | ChEMBL. | 7277393 |
Days (functional) | = 12.2 | Effect on P-388 lymphocytic leukemia growth at a given dose 10 mg/kg per day ip expressed as average survival days of treated mice | ChEMBL. | 7277393 |
Inhibition (functional) | = 92.4 % | Percent inhibition of ehrlich ascites carcinoma growth at 10 mg/kg per day | ChEMBL. | 7277393 |
Inhibition (functional) | = 92.4 % | Percent inhibition of ehrlich ascites carcinoma growth at 10 mg/kg per day | ChEMBL. | 7277393 |
Survivors at day 9 (functional) | = 8 | Effect on ehrlich ascites carcinoma growth in CF1 mice at 10 mg/kg per day ip survival at day 9; 8/8 | ChEMBL. | 7277393 |
T/C (functional) | = 101 | Effect of compound on P-388 lymphocytic leukemia growth at a given dose 15 mg/kg per day ip expressed as ratio of treated / control (T/C>125 is required for significant activity) | ChEMBL. | 7277393 |
T/C (functional) | = 109 | Effect of compound on P-388 lymphocytic leukemia growth at a given dose 5 mg/kg per day ip expressed as ratio of treated / control (T/C>125 is required for significant activity) | ChEMBL. | 7277393 |
T/C (functional) | = 128 | Effect of compound on P-388 lymphocytic leukemia growth at a given dose 10 mg/kg per day ip expressed as ratio of treated / control (T/C>125 is required for significant activity) | ChEMBL. | 7277393 |
Volume (functional) | = 0.54 | Percent packed cell volume at 10 mg/kg per day per mouse | ChEMBL. | 7277393 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.